Vanda Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 203
- Market Cap
- $311.8M
- Introduction
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT03838926
- Locations
- 🇺🇸
Vanda Investigational Site, Seattle, Washington, United States
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT03772340
- Locations
- 🇺🇸
Vanda Investigational Site, Santa Monica, California, United States
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 375
- Registration Number
- NCT03568331
- Locations
- 🇺🇸
Vanda Investigational Site, Spokane, Washington, United States
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT03373201
- Locations
- 🇺🇸
Vanda Investigational Site, Houston, Texas, United States
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT03291041
- Locations
- 🇺🇸
Vanda Investigational Site, Chevy Chase, Maryland, United States
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
- Conditions
- Sleep Disturbances in Smith-Magenis Syndrome
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT03154697
- Locations
- 🇺🇸
Vanda Pharmaceuticals, Washington, District of Columbia, United States
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
- Conditions
- Gastroparesis
- Interventions
- Other: PlaceboDrug: VLY-686 (Tradipitant)
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT02970968
- Locations
- 🇺🇸
Vanda Investigational Site, Norfolk, Virginia, United States
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
- Conditions
- Circadian Rhythm Sleep DisordersNon-24 Hour Sleep-Wake DisorderAutism Spectrum DisorderSmith-Magenis Syndrome
- Interventions
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02776215
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT02651714
- Locations
- 🇺🇸
Vanda Investigational Site, Spokane, Washington, United States
Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02621385
- Locations
- 🇨🇭
Vanda Investigational Site, Arzo, Switzerland